Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, has announced that it will release its fiscal 2024 third quarter financial results on Tuesday, August 6, 2024. The company, which focuses on developing therapeutics for various neurological conditions, will host a conference call and webcast at 8:30 am ET on the same day. During this call, management will review the financial results and provide an update on the company's growth strategy. Investors and interested parties can access the webcast through Anavex's website or join the conference call by dialing 1 929 205 6099 (U.S. participants) using the Meeting ID# 821 9280 7728 and passcode 121725. A replay of the call will be available on the company's website for up to 30 days.
Anavex Life Sciences Corp. (Nasdaq: AVXL), azienda biofarmaceutica in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre fiscale 2024 il martedì 6 agosto 2024. L'azienda, che si concentra sullo sviluppo di terapeutiche per varie condizioni neurologiche, terrà una conference call e webcast alle 8:30 ET dello stesso giorno. Durante questa chiamata, il management esaminerà i risultati finanziari e fornirà un aggiornamento sulla strategia di crescita dell'azienda. Gli investitori e le parti interessate possono accedere al webcast tramite il sito web di Anavex o partecipare alla conference call componendo il numero 1 929 205 6099 (partecipanti statunitensi) usando l'ID Riunione# 821 9280 7728 e il codice di accesso 121725. Una registrazione della chiamata sarà disponibile sul sito dell'azienda per un massimo di 30 giorni.
Anavex Life Sciences Corp. (Nasdaq: AVXL), una empresa biofarmacéutica en etapa clínica, ha anunciado que publicará sus resultados financieros del tercer trimestre fiscal 2024 el martes 6 de agosto de 2024. La compañía, que se centra en desarrollar terapias para diversas condiciones neurológicas, llevará a cabo una conferencia telefónica y webcast a las 8:30 am ET del mismo día. Durante esta llamada, la dirección revisará los resultados financieros y proporcionará una actualización sobre la estrategia de crecimiento de la compañía. Los inversores y partes interesadas pueden acceder al webcast a través del sitio web de Anavex o unirse a la conferencia telefónica marcando el 1 929 205 6099 (participantes de EE. UU.) utilizando el ID de reunión# 821 9280 7728 y el código de acceso 121725. Una grabación de la llamada estará disponible en el sitio web de la compañía durante un máximo de 30 días.
Anavex Life Sciences Corp. (Nasdaq: AVXL)는 임상 단계의 생명공학 회사로 2024 회계연도 3분기 재무 결과를 2024년 8월 6일 화요일에 발표할 것이라고 발표했습니다. 다양한 신경학적 질환에 대한 치료제를 개발하는 데 집중하는 이 회사는 같은 날 오전 8시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 이 콜 동안 경영진은 재무 결과를 검토하고 회사의 성장 전략에 대한 업데이트를 제공할 것입니다. 투자자 및 관심이 있는 사람들은 Anavex의 웹사이트를 통해 웹캐스트에 접속하거나 미국 참여자가 1 929 205 6099로 전화하여 회의 ID# 821 9280 7728과 비밀번호 121725로 컨퍼런스 콜에 참여할 수 있습니다. 콜의 재생은 회사 웹사이트에서 최대 30일 동안 제공될 것입니다.
Anavex Life Sciences Corp. (Nasdaq: AVXL), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre fiscal 2024 le mardi 6 août 2024. L'entreprise, qui se concentre sur le développement de thérapies pour diverses affections neurologiques, organisera une conférence téléphonique et webcast à 8h30 ET le même jour. Lors de cet appel, la direction passera en revue les résultats financiers et fournira une mise à jour sur la stratégie de croissance de l'entreprise. Les investisseurs et les parties intéressées peuvent accéder au webcast via le site Web d'Anavex ou rejoindre la conférence téléphonique en composant le 1 929 205 6099 (participants américains) en utilisant l'ID de réunion# 821 9280 7728 et le code d'accès 121725. Un enregistrement de l'appel sera disponible sur le site web de l'entreprise pendant 30 jours maximum.
Anavex Life Sciences Corp. (Nasdaq: AVXL), ein klinisch tätiges biopharmazeutisches Unternehmen, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal des Geschäftsjahres 2024 am Dienstag, den 6. August 2024 veröffentlichen wird. Das Unternehmen, das sich auf die Entwicklung von Therapeutika für verschiedene neurologische Erkrankungen konzentriert, wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Während dieses Anrufs wird das Management die Finanzergebnisse überprüfen und ein Update zur Wachstumsstrategie des Unternehmens geben. Investoren und interessierte Parteien können über die Website von Anavex auf den Webcast zugreifen oder sich der Telefonkonferenz anschließen, indem sie 1 929 205 6099 (US-Teilnehmer) wählen und die Meeting-ID# 821 9280 7728 sowie den Zugangscode 121725 verwenden. Eine Aufzeichnung des Anrufs wird bis zu 30 Tage auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended June 30, 2024, on Tuesday, August 6, 2024.
Management will host a conference call on Tuesday, August 6, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.
The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 821 9280 7728 and reference passcode 121725. A replay of the conference call will also be available on Anavex’s website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When will Anavex Life Sciences (AVXL) release its fiscal 2024 Q3 financial results?
What time is Anavex Life Sciences' (AVXL) Q3 2024 earnings call scheduled for?
How can investors access Anavex Life Sciences' (AVXL) Q3 2024 earnings call?
What therapeutic areas does Anavex Life Sciences (AVXL) focus on?
